Cytek Biosciences, Inc. (CTKB) Reports In-Line Q3 EPS ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CTKB Hot Sheet
Join SI Premium – FREE
Cytek Biosciences, Inc. (NASDAQ: CTKB) reported Q3 EPS of $0.01, in-line with the analyst estimate of $0.01. Revenue for the quarter came in at $51.5 million versus the consensus estimate of $50.7 million.
GUIDANCE:
Cytek Biosciences, Inc. sees FY2024 revenue of $203-210 million, versus the consensus of $203.9 million.
For earnings history and earnings-related data on Cytek Biosciences, Inc. (CTKB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Therma Bright plans $420,000 non-brokered private placement
- Goldcana closes $1M private placement of flow-through shares
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
